Medacta Group SA · SIX:MOVE
Medacta Group SA — H1 2022 Earnings Presentation
17 slides from Medacta Group SA's earnings presentation, Sep 9, 2022
Slide 1: 1H 2022 Financial Results
1H 2022 Financial Results 9 September 2022
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou
Slide 3: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer 1H 2022 Financial Results
Slide 4: 1H 2022 Key Financial Figures
1H 2022 Key Financial Figures* * Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free Ca
Slide 5: 1H 2022 Highlights
1H 2022 Highlights Significant customer acquisition, salesforce expansion and product introduction drove the revenue growth that was limited by pandemic restrictions and hospital staffing shortages in Australia and U.S. Compared to 1H 2019, revenue CAGR of 10.9% at constant currency; true growth
Slide 6: 1H 2022 Revenue Bridge by Product Line
1H 2022 Revenue1 Bridge by Product Line 11.1% 16.1% 35.6% 16.0% 14.6% 19.0% 19.8; 9% (€m, %) 12.9; 6% (€m) 101.4; 48% 77.2; 37% 2 Hip Knee Extremities Spine Hip: growth driven by the AMIS® strategy, supported by further adoption of the Bikini technique, and the roll-out of new products Knee: goo
Slide 7: 1H 2022 Revenue Bridge by Geographic Area
1H 2022 Revenue1 Bridge by Geographic Area 22.0% 10.8% 3.7% 31.8% 14.6% 19.0% 7.9; 4% (€m, %) (€m) 44.8; 21% 94.4; 45% 64.2; 30% Europe NA APAC ROW In 1H 2022 the geographic mix from prior period shows a shift from APAC to Europe mainly due to Covid-19 restrictions in Australia Europe: solid growt
Slide 8: 1H 2019-2022 True Growth beyond a Mere Recovery
1H 2019-2022 True Growth beyond a Mere Recovery 1H 2019-2022 Revenue1 Trend by Product Line 101.4 (€m) 88.4 82.9 77.2 1 68.9 REVENUE CAGR 63.4 2 53.7 1H 2019-2022 47.3 HIP 6.3% KNEE 11.9% 16.6 19.8 SPINE 21.9% 10.9 12.5 9.1 12.9 EXTREMITIES 44.5% 4.2 6.1 Total 10.9% 1H19 1H20 1H21 1H22 Total 151.6 1
Slide 9: Corrado Farsetta, Chief Financial Officer
CORRADO FARSETTA Chief Financial Officer 1H 2022 Financial Results
Slide 10: 1H 2022 P&L
1H 2022 P&L1 PROFIT & LOSS STATEMENT (€m) 1H 2021 A 1H 2022 A Revenues 177.5 211.3 Cost of Sales (48.9) (62.9) GROSS PROFIT 128.6 148.4 GROSS PROFIT MARGIN 72.5% 70.2% CORE Research and Development (4.5) (7.5) CORE Sales and Marketing expenses (61.0) (77.1) CORE General and Administrative (24.9) (29
Slide 11: Investments for Future Growth
1H 2022 Investments for Future Growth 1H 2022 Investments EUR 36.2m % of Revenues 17.1% ~90% of Capex driven by volume growth (€m) Other 2 Investments in surgical instruments to Intangibles; 0.7; 2% serve new customers started in 2022 R&D Investments; Instruments; Other tangible investments incl
Slide 12: Free Cash Flow
1H 2022 Free Cash Flow1 ADJUSTED FREE CASH FLOW (€m) 1H 2021 A 1H 2022 A PROFIT FOR THE PERIOD 29.7 25.6 P&L Adjustments: Income tax expenses 1.9 4.9 Depreciation and amortisation 18.5 24.3 Other P&L non-cash transactions 5.6 6.1 Movements in working capital and other (40.2) (29.8) CASH FLOW FROM OP
Slide 13: Net Financial Debt: Strong Liquidity and Well Funded for Future Growth
Net Financial Debt: Strong Liquidity and Well Funded for Future Growth (€M) 1 Notes: 1. Other includes Euro 9.9 million of currency translation effect, Euro 3.4 million of lease liabilities repayment and Euro 1.1 million of purchase of treasure shares. 13
Slide 14: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer 1H 2022 Financial Results
Slide 15: 2022 Outlook
2022 Outlook We revise upward our 2022 revenue growth guidance in the range of 14% to 16%, at constant currency. Following the persistently less favorable revenue geographic mix, together with inflationary costs due to macroeconomic and geopolitical issues, adjusted EBITDA margin is now expected a
Slide 16: Q&A 1H 2022 Financial Results
Q&A 1H 2022 Financial Results
Slide 17: Adedacta International
Adedacta International